Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Nelotanserin (Primary)
- Indications REM-sleep-behavior-disorder
- Focus Registrational; Therapeutic Use
- Sponsors Axovant Gene Therapies; Axovant Sciences; Sio Gene Therapies [CEASED]
- 22 Jun 2021 Results presented at the 7th Congress of the European Academy of Neurology
- 10 Dec 2018 Top-line results (n=34) are presented in an Axovant media release.
- 10 Dec 2018 Primary endpoint has not been met. (frequency of REM sleep), according to an Axovant media release.